文献速递乳腺癌

全基因组测序揭示家族性乳腺癌病因学的临床相关见解

Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
PubMed 文献 · Ann Oncol · 2019-01-01

本研究对78例家族性乳腺癌高风险个体的配对种系与肿瘤DNA进行全基因组测序,其中BRCA1致病性变异携带者26例、BRCA2携带者22例、非BRCA1/2携带者30例。研究发现BRCA1携带者100%的肿瘤和BRCA2携带者91%的肿瘤呈现相应基因的双等位基因失活,并伴有提示同源重组功能缺陷的体细胞突变特征;部分非BRCA1/2肿瘤也具有提示BRCA缺陷的体细胞特征。全基因组测序衍生的特征比种系状态及其他同源重组缺陷基因组预测因子更稳健,可影响铂类或PARP抑制剂治疗的选择。

要点

  • BRCA1携带者100%的肿瘤和BRCA2携带者91%的肿瘤呈现相应基因双等位基因失活。
  • 部分非BRCA1/2肿瘤具有提示BRCA缺陷的体细胞突变特征。
  • 全基因组测序衍生的特征比种系状态及其他同源重组缺陷基因组预测因子更稳健。

核心结论

  • 配对种系/肿瘤DNA的全基因组测序及体细胞突变特征有助于发现致病性种系变异并为变异致病性提供支持证据。
  • 全基因组测序衍生的特征比种系状态及其他同源重组缺陷基因组预测因子更稳健,从而影响铂类或PARP抑制剂治疗的选择。
  • 这是首次通过全基因组测序检查非BRCA1/2肿瘤,揭示了这些肿瘤基因组的显著异质性,并强调复杂基因组重排可能驱动部分病例的肿瘤发生。

研究设计与样本

  • 对78例配对种系与肿瘤DNA样本进行全基因组测序,样本来自BRCA1致病性变异携带者26例、BRCA2致病性变异携带者22例及非BRCA1/2携带者30例。

主要发现

  • 配对种系/肿瘤全基因组测序及体细胞突变特征分析发现了未报告的癌症风险基因双致病性种系变异(BRCA1/BRCA2;BRCA1/MUTYH)。
  • BRCA1携带者100%的肿瘤和BRCA2携带者91%的肿瘤呈现相应基因的双等位基因失活,并伴有提示同源重组功能缺陷的体细胞突变特征。
  • 一组非BRCA1/2肿瘤也具有提示BRCA缺陷的体细胞特征,包括BRCA1启动子甲基化的肿瘤以及PALB2致病性种系变异携带者和BRCA2意义不确定变异携带者的肿瘤。
  • 13例非BRCA1/2早发肿瘤的一个亚组为BRCA功能正常,但显示与癌基因扩增及TP53、ATM和CHEK2致病性种系变异相关的复杂聚集性结构重排。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whole-genome sequencing (WGS) is a powerful method for revealing the diversity and complexity of the somatic mutation burden of tumours. Here, we investigated the utility of tumour and matched germline WGS for understanding aetiology and treatment opportunities for high-risk individuals with familial breast cancer. PATIENTS AND METHODS: We carried out WGS on 78 paired germline and tumour DNA samples from individuals carrying pathogenic variants in BRCA1 (n = 26) or BRCA2 (n = 22) or from non-carriers (non-BRCA1/2; n = 30). RESULTS: Matched germline/tumour WGS and somatic mutational signature analysis revealed patients with unreported, dual pathogenic germline variants in cancer risk genes (BRCA1/BRCA2; BRCA1/MUTYH). The strategy identified that 100% of tumours from BRCA1 carriers and 91% of tumours from BRCA2 carriers exhibited biallelic inactivation of the respective gene, together with somatic mutational signatures suggestive of a functional deficiency in homologous recombination. A set of non-BRCA1/2 tumours also had somatic signatures indicative of BRCA-deficiency, including tumours with BRCA1 promoter methylation, and tumours from carriers of a PALB2 pathogenic germline variant and a BRCA2 variant of uncertain significance. A subset of 13 non-BRCA1/2 tumours from early onset cases were BRCA-proficient, yet displayed complex clustered structural rearrangements associated with the amplification of oncogenes and pathogenic germline variants in TP53, ATM and CHEK2. CONCLUSIONS: Our study highlights the role that WGS of matched germline/tumour DNA and the somatic mutational signatures can play in the discovery of pathogenic germline variants and for providing supporting evidence for variant pathogenicity. WGS-derived signatures were more robust than germline status and other genomic predictors of homologous recombination deficiency, thus impacting the selection of platinum-based or PARP inhibitor therapy. In this first examination of non-BRCA1/2 tumours by WGS, we illustrate the considerable heterogeneity of these tumour genomes and highlight that complex genomic rearrangements may drive tumourigenesis in a subset of cases.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Nones K, Johnson J, Newell F, et al. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Ann Oncol. 2019. PMID: 31090900. doi:10.1093/annonc/mdz132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。